PTC Therapeutics, Inc. PTCT R2KR3KPHARMA

Q: What is the current share price of PTC Therapeutics, Inc. (PTCT)?

As of 2026-09-07 16:24 PDT, PTC Therapeutics, Inc. (PTCT) trades at $69.30 on NasdaqGS. Its 52-week range is $48.17 to $89.55.

Q: What is the market capitalisation of PTCT?

PTC Therapeutics, Inc. (PTCT) has a market capitalisation of $5.78B on NasdaqGS.

Q: What is the P/E ratio of PTCT?

PTCT trades at a trailing price-to-earnings (P/E) ratio of -103.43. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -36.93.

Q: Is PTCT a good stock to buy?

This page provides a data-driven analysis of PTC Therapeutics, Inc. (PTCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.ptcbio.com

Company Profile ↓

$69.30

+43.87% 1Y

Mkt Cap$5.78B

P/E-103.43

P/B-36.93

52W High$89.55

52W Low$48.17

Book Value$-1.99

EPS (TTM)$-0.67

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 44.9%.

Consistent Profit Growth

Net profit has compounded at 24.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 22.1% CAGR over the past five years.

Healthy Margins

Operating margin of 41.3% supports profitability.

Recent Developments

Dec 2025 Revenue of $1.73B (+114.5% YoY); net profit $682.64M.
Trailing 12 Months Year-on-year growth — revenue +101.5%.
5-Year Trend Long-term compounding — revenue CAGR 22.1%, profit CAGR 24.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	22.13%
1 Year:	101.50%

Compounded Profit Growth

5 Years:	24.74%
1 Year:	-

Stock Price Performance

1 Year:	+43.87%
6 Months:	+10.32%
3 Months:	-2.35%
1 Month:	-2.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 51% of range

$48.17 $89.55

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)40.76 · Neutral

Price Performance

1M-2.19%

3M-2.35%

6M+10.32%

1Y+43.87%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Healthy ROCE of 44.9%.
Compounding revenue at 22.1% over 5 years.
Profit CAGR of 24.7% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-103.43

Industry PE

25.17

Forward P/E

27.72

PEG Ratio

Book Value

$-1.99

Price to Book

-36.93

P/S

6.07

EV/EBITDA

40.35

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

22.13%

Profit 5Y

24.74%

Revenue (YoY)

101.50%

Earnings (YoY)

Profitability & Returns

ROCE

44.91%

ROE

ROA

2.46%

Profit Margin

-3.81%

Op Margin

41.32%

Gross Margin

49.96%

EPS (Latest Qtr)

$0.92

EPS (TTM)

$-0.67

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

3.20

Current Ratio

3.39

Debt

$3.02B

Total Assets

$3.25B

Current Assets

Working Capital

Ownership

Promoter Holding

7.31%

Chg in Prom Hold

-0.07%

FII / Inst Holding

122.93%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$5.78B

Total Revenue (TTM)

$1.01B

EBITDA

$171.22M

Free Cash Flow

$-286.80M

Operating Cash Flow

$-30.50M

Shares Outstanding

83.46M

Gross Margin

49.96%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PTCT PTC Therapeutics, Inc. R2KR3KPHARMA	69.30	-103.43	$5.78B	0.00%	44.91%	-	22.13%	24.74%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71.42M	-	68.26M	75.24M	118.40M	-	117.94M	116.68M	138.74M	148.74M	165.53M	217.13M	220.38M	213.81M	196.58M	210.12M	186.70M	196.79M	1.18B	178.88M	211.01M	272.55M	360.52M
Operating Income	-38.63M	-42.23M	-48.20M	-38.44M	-36.56M	-32.06M	-24.99M	-26.36M	-12.50M	-30.89M	5.45M	-16.74M	-5.57M	-48.23M	-45.14M	-69.14M	-38.76M	-60.48M	-72.78M	-92.99M	-187.27M	-55.13M	-96.37M	-98.15M	-98.49M	-93.08M	-86.52M	-92.36M	-68.19M	-117.61M	-209.54M	-118.16M	-45.45M	-40.22M	-54.51M	970.23M	-34.96M	3.02M	44.96M	148.98M
Net Income	-38.36M	-43.22M	-50.95M	-41.23M	-38.91M	-35.17M	-26.80M	-29.06M	-17.48M	-33.74M	1.27M	-19.26M	-9.52M	-50.97M	-48.33M	-72.11M	-41.79M	-60.00M	-77.68M	-112.69M	-181.43M	-69.69M	-74.35M	-128.64M	-118.37M	-133.62M	-126.73M	-152.09M	-109.31M	-138.96M	-198.88M	-132.97M	-91.58M	-99.18M	-106.65M	866.56M	-64.85M	15.90M	-2.81M	83.50M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.83	-1.68	-1.89	-1.78	-2.13	-1.53	-1.88	-2.66	-1.76	-1.20	-1.29	-1.39	10.04	-0.83	0.20	-0.03	0.92
R&D Expense	28.19M	30.64M	-	31.40M	28.83M	31.40M	-	27.36M	30.84M	30.02M	-	31.36M	32.61M	54.37M	-	52.57M	59.98M	63.08M	-	90.11M	176.53M	93.00M	-	134.51M	125.48M	130.84M	140.08M	157.26M	165.46M	195.12M	185.87M	164.21M	116.13M	132.17M	161.41M	108.97M	112.99M	100.16M	100.87M	99.15M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	105.41M	33.95M	34.70M	25.25M	36.77M	82.70M	194.39M	264.73M	306.98M	380.77M	538.59M	698.80M	937.82M	806.78M	1.73B
Operating Income	30.58M	-26.81M	-45.40M	-99.41M	-167.13M	-132.06M	-64.29M	-115.69M	-241.16M	-431.77M	-374.44M	-447.41M	-439.50M	-302.57M	866.93M
Net Income	30.90M	-26.23M	-51.57M	-93.75M	-170.45M	-142.11M	-79.00M	-128.08M	-251.58M	-438.16M	-523.90M	-559.02M	-626.60M	-363.30M	682.64M
Diluted EPS	4.55	42.50	-5.18	-2.97	-	-	-	-	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73	7.78
R&D Expense	58.68M	46.14M	54.88M	79.84M	121.82M	117.63M	117.46M	171.98M	257.45M	477.64M	540.68M	651.50M	666.56M	534.48M	455.25M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	13.07M	151.90M	333.22M	365.28M	269.35M	391.65M	1.12B	1.62B	2.21B	1.94B	1.71B	1.90B	1.71B	2.90B
Total Equity	-272.33M	-238.60M	-99.64M	136.54M	298.47M	226.00M	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.10B	-205.31M
Cash & Equivalents	28.67M	28.43M	2.73M	15.41M	49.75M	58.02M	58.32M	111.79M	169.50M	288.03M	208.81M	189.72M	279.83M	594.00M	779.71M	984.65M
Long Term Debt	-	-	438.81K	-	-	91.85M	98.22M	144.97M	141.35M	293.86M	309.14M	281.89M	571.72M	284.21M	285.41M	-
Total Liabilities	-	-	31.89M	15.36M	34.75M	139.28M	149.76M	235.22M	768.50M	1.03B	1.73B	1.94B	2.05B	2.71B	2.80B	3.10B
Current Liabilities	-	-	28.16M	13.13M	32.48M	45.39M	49.62M	82.05M	166.80M	235.86M	277.33M	509.35M	406.24M	603.10M	580.98M	968.43M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-57.27M	-124.34M	-103.57M	-10.06M	-27.64M	-98.64M	-194.07M	-251.33M	-356.65M	-158.42M	-107.69M	711.20M
Investing Cash Flow	-	-	-	-145.17M	-20.81M	104.48M	13.12M	-42.61M	-387.24M	-561.55M	219.18M	290.18M	-176.74M	44.18M	-861.98M
Financing Cash Flow	-	-	-	237.13M	154.06M	968.00K	44.22M	131.57M	613.21M	668.72M	20.88M	167.95M	646.40M	255.87M	331.09M
Capital Expenditure	-165.12K	-189.00K	-846.00K	-4.66M	-2.72M	-1.78M	-3.10M	-7.10M	-13.76M	-17.84M	-28.21M	-32.02M	-28.44M	-6.50M	-8.86M
Free Cash Flow	-	-	-	-61.94M	-127.06M	-105.34M	-13.16M	-34.74M	-112.40M	-211.91M	-279.55M	-388.67M	-186.86M	-114.19M	702.34M

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	29.0%	-79.0%	-130.8%	-393.8%	-454.6%	-159.7%	-33.1%	-43.7%	-78.6%	-113.4%	-69.5%	-64.0%	-46.9%	-37.5%	50.1%
Net Margin %	29.3%	-77.3%	-148.6%	-371.4%	-463.6%	-171.8%	-40.6%	-48.4%	-82.0%	-115.1%	-97.3%	-80.0%	-66.8%	-45.0%	39.4%
ROE %	-13.0%	26.3%	-37.8%	-31.4%	-75.4%	-118.8%	-50.5%	-36.5%	-42.3%	-90.9%	-36,432.6%	161.1%	76.6%	33.1%	-332.5%
ROCE %	-	177.7%	-32.7%	-33.1%	-52.2%	-60.1%	-20.8%	-12.1%	-17.4%	-22.4%	-26.2%	-34.4%	-34.0%	-26.9%	44.9%

Shareholding Pattern

Insiders

7.31%

Institutions

122.93%

Public Float

132.62%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	16.73%	13.96M	$978.78M
2	RTW Investments LP	9.28%	7.75M	$542.95M
3	Jupiter Topco LLC	8.67%	7.24M	$507.20M
4	Vanguard Portfolio Management LLC	5.90%	4.93M	$345.41M
5	State Street Corporation	5.51%	4.60M	$322.34M
6	Wellington Management Group, LLP	4.95%	4.13M	$289.35M
7	Vanguard Capital Management LLC	4.48%	3.74M	$262.08M
8	Geode Capital Management, LLC	2.64%	2.21M	$154.71M
9	Toronto Dominion Bank	2.60%	2.17M	$151.80M
10	Westfield Capital Management Co LP	2.34%	1.96M	$137.11M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PTCT

Google News Sun, 06 Sep 2026

PTC Therapeutics (PTCT) Shares New Sephience Data, Is The Stock A Bargain? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQMER6aHl4X2VCbWxZeW93RUk0ek9oclpTU1JrM3JrNGJIOGdSTFZ2TUFrMjRFTDlVamd3UmRib2RVYWxkM0YydmJqd3FYQUtNdlVrM3JmQjlVS2JGbXNhT3E1eWpSOUM3WGw1QkNvN0FDbmtGVUlVbDFhZHJtNnpWd1dJMmVfaUc2LTJNQk…

Google News Sat, 11 Jul 2026

PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNemZ2NmJKdjA1cHZ4OG91SEVlcWpMcGdPYWdBTWdlZ0Vfb0M2UGVXYmFmaWJRNVVRNnlTbG1jS0dTa3FER3h0QTFNQmE1Yy1VYmpzZFMzOHp6UGFaSVNUSi1UbzZhcUZjcFFfRU1wQ2NFN3RRRTFldkRURDdrVlVjaWduQUFwRHlPLUx2eE…

Google News Fri, 28 Aug 2026

Insider Sale: Director at $PTCT Sells 5,626 Shares - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOVjh3ZDJlVEhLQlNIU3gtcnVnd3k4MW51TG16VHU5S0FZSW1DTGNRSWwyNEJER3kwb0F5dHcwQ0tFN09MSlQtTXZJSUpXRGMtcndPUHZmZC1FcHlXUmpjVkZzS1FPWlFONU44SHRKd0U2bzVfaUxLeUZuVlBZUDlvZTVXT0NjMUc0VldYZj…

Google News hu, 27 Aug 2026

PTC Therapeutics executives will speak at three September healthcare conferences - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNTF9ULUhtRkI5MWt5T1hNMUFoTURCVXVScVh2SktfcDl5QmpUbjNlNDdpa2VWc3JGRGdTbV9iWHd4c1ZlNjYtbTlPanEwRm5JZXhSc3BYZ3dVTUZIRXd1NjV0UWFzZ1pNbVh6R0JMWmktZ2JaNUxsX1NOeEw1OEtzNVB6eG50NHA4SWVlZU…

Google News hu, 30 Apr 2026

PTC Therapeutics Stock To $84? - Trefis

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNZlMwZlMyazlleDZ2RkhxR0FENkdsckk3MjE3bW9Tc2pTTjFoMGttSHhsWm9mVVppbU12N21SRHgzMVFsVy16ZWNWQVZZWDZEWm9DS2htSW1IOUxOVHZhS0NuUG5rdm1WOGpVV2FOaGt1WVZidExKZ3BuaFZMN0pTekwtSnQxZjhzbWJOaD…

Google News Fri, 28 Aug 2026

Michael Schmertzler Sells 12,500 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPSUptZ2kyOHpTN1Q4Q3hfWXE3SE5wX0R2Yk1QRWtZODVUVVZMOHZqTnNNSEVqMnRrdGREaXNjVjZuWXFFdVl3WTk0NENxNFlTb1dReU1KT0J6NWNRbXpwQVhIMmFYdUk0SnFQOThaX2RKTTkxTmIzUWdQR0hONTN5RnVaT21rZlgxNHlmWW…

PTCT — Frequently Asked Questions

What is the current share price of PTC Therapeutics, Inc. (PTCT)?

As of 2026-09-07 16:24 PDT, PTC Therapeutics, Inc. (PTCT) trades at $69.30 on NasdaqGS. Its 52-week range is $48.17 to $89.55.

What is the market capitalisation of PTCT?

PTC Therapeutics, Inc. (PTCT) has a market capitalisation of $5.78B on NasdaqGS.

What is the P/E ratio of PTCT?

PTCT trades at a trailing price-to-earnings (P/E) ratio of -103.43. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -36.93.

Is PTCT a good stock to buy?

This page provides a data-driven analysis of PTC Therapeutics, Inc. (PTCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

PTC Therapeutics, Inc. PTCT R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

PTC Therapeutics (PTCT) Shares New Sephience Data, Is The Stock A Bargain? - simplywall.st

PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data - Yahoo Finance

Insider Sale: Director at $PTCT Sells 5,626 Shares - quiverquant.com

PTC Therapeutics executives will speak at three September healthcare conferences - Stock Titan

PTC Therapeutics Stock To $84? - Trefis

Michael Schmertzler Sells 12,500 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - marketbeat.com

PTCT — Frequently Asked Questions

What is the current share price of PTC Therapeutics, Inc. (PTCT)?

What is the market capitalisation of PTCT?

What is the P/E ratio of PTCT?

Is PTCT a good stock to buy?

Explore More